[go: up one dir, main page]

BR9508261A - Enterically coated oral formulation using the same process to prepare the formulation to inhibit gastric acid secretion in mammals and humans and to treat gastric acid-related diseases in humans and humans and cross-pressure blister pack - Google Patents

Enterically coated oral formulation using the same process to prepare the formulation to inhibit gastric acid secretion in mammals and humans and to treat gastric acid-related diseases in humans and humans and cross-pressure blister pack

Info

Publication number
BR9508261A
BR9508261A BR9508261A BR9508261A BR9508261A BR 9508261 A BR9508261 A BR 9508261A BR 9508261 A BR9508261 A BR 9508261A BR 9508261 A BR9508261 A BR 9508261A BR 9508261 A BR9508261 A BR 9508261A
Authority
BR
Brazil
Prior art keywords
humans
gastric acid
formulation
mammals
prepare
Prior art date
Application number
BR9508261A
Other languages
Portuguese (pt)
Inventor
Siv Inga Bengtsson
Kurt Ingmar Loevgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of BR9508261A publication Critical patent/BR9508261A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR9508261A 1994-07-08 1995-07-03 Enterically coated oral formulation using the same process to prepare the formulation to inhibit gastric acid secretion in mammals and humans and to treat gastric acid-related diseases in humans and humans and cross-pressure blister pack BR9508261A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9400679 1994-07-08
PCT/SE1995/000816 WO1996001622A1 (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole

Publications (1)

Publication Number Publication Date
BR9508261A true BR9508261A (en) 1997-12-23

Family

ID=20393105

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9508261A BR9508261A (en) 1994-07-08 1995-07-03 Enterically coated oral formulation using the same process to prepare the formulation to inhibit gastric acid secretion in mammals and humans and to treat gastric acid-related diseases in humans and humans and cross-pressure blister pack

Country Status (15)

Country Link
EP (1) EP0768872A1 (en)
KR (1) KR970704426A (en)
BR (1) BR9508261A (en)
CA (1) CA2193681A1 (en)
CZ (1) CZ379596A3 (en)
EE (1) EE03378B1 (en)
FI (1) FI970058A0 (en)
HU (1) HUT78132A (en)
IS (1) IS4398A (en)
MX (1) MX9700152A (en)
NO (1) NO970036D0 (en)
NZ (1) NZ289958A (en)
PL (1) PL181265B1 (en)
SK (1) SK281803B6 (en)
WO (1) WO1996001622A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5900258A (en) * 1996-02-01 1999-05-04 Zeolitics Inc. Anti-bacterial compositions
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9802973D0 (en) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
AU3762801A (en) * 2000-03-09 2001-09-17 Andrew Ilchyshyn Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1552833B1 (en) 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006002077A2 (en) * 2004-06-15 2006-01-05 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of benzimidazole compounds
CN105106168B (en) * 2015-08-19 2018-03-06 德州德药制药有限公司 A kind of esomeprazole magnesium intestines capsule and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (en) * 1988-05-18 1995-07-26 エーザイ株式会社 Oral formulation of acid labile compounds
SE9302395D0 (en) * 1993-07-09 1993-07-09 Ab Astra NEW PHARMACEUTICAL FORMULATION
SE9302396D0 (en) * 1993-07-09 1993-07-09 Ab Astra A NOVEL COMPOUND FORM

Also Published As

Publication number Publication date
EE03378B1 (en) 2001-04-16
EE9700014A (en) 1997-06-16
CZ379596A3 (en) 1997-08-13
MX9700152A (en) 1997-04-30
NO970036L (en) 1997-01-06
IS4398A (en) 1996-12-17
KR970704426A (en) 1997-09-06
SK166096A3 (en) 1997-09-10
AU2994795A (en) 1996-02-09
CA2193681A1 (en) 1996-01-25
EP0768872A1 (en) 1997-04-23
NZ289958A (en) 1998-09-24
FI970058L (en) 1997-01-07
FI970058A7 (en) 1997-01-07
PL181265B1 (en) 2001-06-29
HU9700039D0 (en) 1997-02-28
FI970058A0 (en) 1997-01-07
NO970036D0 (en) 1997-01-06
AU695723B2 (en) 1998-08-20
SK281803B6 (en) 2001-08-06
PL318464A1 (en) 1997-06-09
WO1996001622A8 (en) 1999-12-23
HUT78132A (en) 2000-06-28
WO1996001622A1 (en) 1996-01-25

Similar Documents

Publication Publication Date Title
BR9508261A (en) Enterically coated oral formulation using the same process to prepare the formulation to inhibit gastric acid secretion in mammals and humans and to treat gastric acid-related diseases in humans and humans and cross-pressure blister pack
EE03774B1 (en) 5-O-Desosaminyl-6-O-methylerythronolide A Derivatives, Process for their Preparation and Use in the Preparation of Bioactive Products
EE03399B1 (en) Spiro-azabicyclic compounds used in therapy and process for their preparation
EE04342B1 (en) Cycloalkane pyridines, process for their preparation, use in the manufacture of medicaments and medicaments containing them
HUP9800034A3 (en) Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
EE03380B1 (en) Pharmaceutical aerosol formulation and process for its preparation
FI945900A7 (en) Benzenesulfonamide derivatives and method for their preparation
EE9700153A (en) Heterocycle-fused pyridines, process for their preparation, use in the manufacture of medicaments and medicaments containing these compounds
EE03568B1 (en) Benzimidazole derivatives, process for their preparation and use
FI972580A7 (en) Products and methods to reduce skin irritation
EE9700060A (en) 2-Aryl-substituted pyridines, process for their preparation, use in the manufacture of medicaments and medicaments containing these compounds
EE9600172A (en) Purin-6-one derivatives, their preparation method, use in the preparation of medicaments and medicaments
FI973031A0 (en) Use of Thiazolium Compounds to Prevent and Restore the Formation of Advanced Glycosylation End Products
EE9800119A (en) Microencapsulated insecticide preparations and the process for their preparation
FI951773A7 (en) Alpha-aminoalkanoic acids and their reduction products
FI953919A7 (en) Pyrrolydenemethyl derivatives and process for their preparation
NO20016068L (en) Use of oxypurine nucleosides for the preparation of a pharmaceutical composition for reducing inflammation in an animal
EE03878B1 (en) 5-O-Desosaminyl-6-O-methylerythronolide A Derivatives, Process for their Preparation and Use in the Preparation of Bioactive Compounds
EE03312B1 (en) Substituted Arylalkylthioalkylthiopyridines for the Control of Helicobacter Bacteria, their Preparation and their Use in the Preparation of Medicinal Products
FI951631A7 (en) Substituted kynurenines, method for their preparation and their use as medicaments
FI953956A0 (en) 2,3-Ring-fused 1,4-dihydropyridines, processes for their preparation and their use as medicaments
PT915662E (en) COATING AND PROCESSING PRODUCTS FOR THE PREPARATION OF THE SAME
FI951217L (en) Roller and machine for peeling and shaping potatoes and similar products
BR8905747A (en) DERIVATIVES OF 1,3,4-TIADIAZOIS 2,5-DISSUBSTITUIDOS, PROCESS FOR THEIR PREPARATION, PESTICIDAL COMPOSITIONS, PROCESS FOR THE PEST FIGHTING AND PROCESS FOR THE PREPARATION OF PESTICIDED COMPOSITES
FI972530L (en) Process for the preparation of substituted 4-ethyl-piperidines and intermediate used in their preparation

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FA8 Dismissal: dismissal - article 36, par. 1 of industrial property law